Betapace/Betapace AF is an antiarrhythmic indicated for:
• the treatment of life threatening ventricular arrhythmias
• the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL)

The most common adverse reactions (≥2%) for Betapace are: fatigue 4%, bradycardia (less than 50 bpm) 3%, dyspnea 3%, proarrhythmia 3%, asthenia 2%, and dizziness 2%.

• Class I or III Antiarrhythmics or other drugs that prolong the QT interval: Avoid concomitant use
• Digoxin, calcium channel blocker: increased risk of bradycardia, hypotension, heart failure
• Dosage of insulin or antidiabetic drugs may need adjustment
• Aluminum or magnesium-based antacids reduce sotalol exposure

• QT prolongation, bradycardia, AV block, hypotension, worsening heart failure: Reduce dose or discontinue
• Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue
• Correct any electrolyte disturbances
• May mask symptoms of hypoglycemia or worsen hyperglycemia in diabetic patients; monitor